CN102716123A - Compound preparation for treating IgA nephropathy - Google Patents
Compound preparation for treating IgA nephropathy Download PDFInfo
- Publication number
- CN102716123A CN102716123A CN2012102286983A CN201210228698A CN102716123A CN 102716123 A CN102716123 A CN 102716123A CN 2012102286983 A CN2012102286983 A CN 2012102286983A CN 201210228698 A CN201210228698 A CN 201210228698A CN 102716123 A CN102716123 A CN 102716123A
- Authority
- CN
- China
- Prior art keywords
- iga nephropathy
- compound preparation
- treating
- probucol
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention discloses a compound preparation for treating IgA nephropathy. The compound preparation for treating the IgA nephropathy consists of the following components in parts by weight: 5-15 parts of sartan medicine and 50 parts of probucol. The compound preparation is obvious in curative effect on slight proteinuria IgA nephropathy, moderate proteinuria IgA nephropathy and severe proteinuria IgA nephropathy. Shown by experimental results, the compound preparation is superior to single reagents, can be used for treating the IgA nephropathy better and is small in side effect.
Description
Technical field
Treatment of kidney disease technical field of the present invention specifically, relates to a kind of IgA nephropathy compound preparation that is used to treat.
Background technology
IgA nephropathy is modal primary glomerulopathy; Account for 30～40% of China's primary glomerulopathy; In being diagnosed as the patient of IgA nephropathy; Had approximately in per 10 years 20% patient be developed to ESRD (end-stage renal disease, the ESRD) stage, the first protopathy that IgA nephropathy has become the chronic Maintenance Hemodialysis Patients of China because of.Thereby improve as much as possible the IgA nephropathy patient therapeutic effect, delay IgA nephropathy patient renal function the deterioration of carrying out property to reducing having very important significance of ESRD.
IgA nephropathy does not still have specific drug treatment at present, the putative treatment guide of neither one yet.The main target of treatment is to reduce albuminuria, alleviate injury of kidney and delay the progress of renal failure.Confirmed that at present the oxidative stress factor brought into play important function in the pathogenic process of IgA nephropathy.Discover that oxidative stress index late protein oxidation product (AOPP) level is the relatively poor independent hazard factor of IgA nephropathy prognosis, the demonstration oxidative stress has also been brought into play important effect in the morbidity of IgA nephropathy.Ang II and oxidative stress factor fellowship the inflammatory reaction of kidney.The former stimulation of renal bead MC produces ultra-oxygen anion free radical (O
2 -), and then the loose and propagation that stimulates MC, and the latter also can stimulate the generation of Ang II, promote glomerule MC loose with fibronectin (fibronectin, synthesizing FN).It is thus clear that, Ang II and oxidative stress factor interaction fellowship the generation and the development of IgA nephropathy.
In the treatment of IgA nephropathy, simultaneously whether blocking oxide stress still not have final conclusion at present.In view of the important function of Ang II in the IgA nephropathy morbidity; Use the active medicine ARB treatment of blocking-up RAS IgA nephropathy to be proved to be effective; But its clinical efficacy is still dissatisfied, even associating angiotensin converting enzyme inhibitor (ACEI) and ARB can not drop to normal range to urine protein; And the Histological change that can not prevent the generation of ESRD fully and improve kidney, prompting simple activation of blocking the RAS system in the therapeutic process of IgA nephropathy is not enough.And use the antioxidant therapy IgA nephropathy separately, though blocked the oxidative stress damage mechanism in the IgA nephropathy morbidity, because of not blocking the activation of RAS system, its curative effect is also undesirable.Based on the fact of Ang II and oxidative stress interaction fellowship inflammatory reaction in the pathogenic process of IgA nephropathy, we infer that blocking oxide stress obtain comparatively ideal curative effect when the therapeutic process of IgA nephropathy.
Summary of the invention
The object of the present invention is to provide a kind of evident in efficacy being used to treat the IgA nephropathy compound preparation.
To achieve these goals, the present invention adopts following technical scheme:
A kind ofly be used to treat the IgA nephropathy compound preparation, form by the component of following parts by weight:
Sartans 5-15
Probucol 50;
Be used for treating the IgA nephropathy compound preparation above-mentioned, preferred parts by weight are:
Sartans 8-15
Probucol 50;
Be used for treating the IgA nephropathy compound preparation above-mentioned, said sartans is preferably valsartan, losartan, irbesartan or telmisartan.The best is valsartan and irbesartan.
Compared with prior art, the present invention has following beneficial effect:
Provided by the inventionly be used to control slight albuminuria IgA nephropathy, moderate albuminuria IgA nephropathy, severe albuminuria IgA nephropathy etc. and all have significant curative effect, experimental result shows that compound preparation is superior to single agent, can the better healing IgA nephropathy, and side effect is little.
The specific embodiment
1. case inclusion criteria:
A. kidney biopsy pathology and clinical definite are the patient of IgA nephropathy;
B. 18～60 years old age;
C. detect conclusive evidence excretion quantity of urinary protein 1.0～2.5g/ days at least 3 times, and eliminating is caused by urinary tract infection or congestive heart failure (3～4 grades of the USA New York heart disease NYHA of association);
D. < 265.2umol/>L is selected in preceding 3 months fluctuating margin and is less than 30% the serum creatinine level;
E. at least 6 weeks do not take ACEI, ARB, antioxidant and hypolipidemic before selected, do not take hormone and Cytotoxic drugs at least in 1 year before selected.
2. case exclusion standard:
A. Secondary cases IgA nephropathy: systemic diseases such as anaphy lactoid purpura nephritis, viral hepatitis, liver cirrhosis, systemic lupus erythematosus (sle) and connective tissue disease;
B. malignant hypertension or acute renal failure;
C. kidney pathology shows as cresentic nephritis;
D. diabetes, renal artery stenosis, obstructive nephropathy, gestation, tumor and activeness digestive tract ulcer;
E. coronary heart disease, cardiomyopathy, arrhythmia, Q-T interval, prolong and the cerebrovascular medical history;
F. infectious disease such as tuberculosis.
3. treatment experiment
(1). screening treatment stage: to meeting the suitable case of selected condition; Collect that the patient is clinical, laboratory and pathological data be as the baseline data; At signature research informed consent postscript, can begin can to get into the stage before the research in the 4 weeks treatment of (run-in phrase).This phase, the each patient accepted probucol500mg/d; 4 weeks of logotype, per 2 weekly check electrocardiograms, routine blood test, as do not have serious side effects such as obvious Q-T interval prolongation, ventricular tachycardia, thrombocytopenia and compliance better; Then carry out random packet, and get into the next stage treatment.
(2). formal treatment stage: after can assessing in the entering stage and screen before the research in 4 weeks, will be selected in the patient and be divided into six groups at random: first group: Probucol 500mg/ days; Second group: valsartan 80mg; The 3rd group: valsartan 80mg/ probucol 500mg/ days; The 4th group: telmisartan 80mg/ days; The 5th group: telmisartan 80mg/ probucol 500mg/ days.The 6th group: irbesartan 150mg; The 7th group: irbesartan 150mg/ probucol 500mg/ days.
(3). observation index:
A. clinical indices: sex, age, body weight, height, body surface area, Body Mass Index, gross hematuria and microscopic hematuria.
B. lab index: serum creatinine level, twenty-four-hour urine PE amount.
C. oxidative stress index: TAC (T-AOC); Adopt hydroxylamine assay, thiobarbituricacid method (TBA method) and colorimetry to detect (test kit builds up bio-engineering research institute available from Nanjing) respectively.
(4). experimental result:
Formal treatment stage: after can assessing in the entering stage and screen before the research in 4 weeks, will be selected in the patient and be divided into six groups at random: first group: probucol 500mg/ days; Second group: valsartan 80mg; The 3rd group: valsartan 80mg/ probucol 500mg/ days; The 4th group: telmisartan 80mg/ days; The 5th group: telmisartan 80mg/ probucol 500mg/ days; The 6th group: irbesartan 150mg; The 7th group: irbesartan 150mg/ probucol 500mg/ days.The variation of renal function and 24 o'clock urine protein when treating for 12 weeks, the result sees table 1.
The result of table 1 shows:
First group of treatment to IgA nephropathy as a comparison do not have positive effect, and second to seven group all has positive effect to the treatment of IgA nephropathy, and wherein, sartans+probucol therapeutic effect is more remarkable.
The modal untoward reaction of these article is a gastrointestinal upset, also has flatulence, stomachache, nausea and vomiting.Other rare reaction has: headache, dizziness, paraesthesia, insomnia, tinnitus, erythra, skin pruritus etc.
The variation of renal function and 24 o'clock urine protein when table 1 treated for 12 weeks
Claims (4)
1. one kind is used to treat the IgA nephropathy compound preparation, it is characterized in that being made up of the component of following parts by weight:
Sartans 5-15
Probucol 50.
2. as claimed in claim 1ly be used to treat the IgA nephropathy compound preparation, it is characterized in that, form by the component of following parts by weight:
Sartans 8-15
Probucol 50.
According to claim 1 or claim 2 be used to treat the IgA nephropathy compound preparation, it is characterized in that said sartans is valsartan, losartan, irbesartan or telmisartan.
4. as claimed in claim 3ly be used to treat the IgA nephropathy compound preparation, it is characterized in that said sartans valsartan or irbesartan.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210228698.3A CN102716123B (en) | 2012-07-04 | 2012-07-04 | Compound preparation for treating IgA nephropathy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210228698.3A CN102716123B (en) | 2012-07-04 | 2012-07-04 | Compound preparation for treating IgA nephropathy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102716123A true CN102716123A (en) | 2012-10-10 |
| CN102716123B CN102716123B (en) | 2014-04-16 |
Family
ID=46942081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210228698.3A Expired - Fee Related CN102716123B (en) | 2012-07-04 | 2012-07-04 | Compound preparation for treating IgA nephropathy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102716123B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105250268A (en) * | 2015-10-26 | 2016-01-20 | 白玲强 | Irbesartan composition and application thereof in preparation of drug for treating acute kidney injury |
| CN109985230A (en) * | 2018-01-02 | 2019-07-09 | 上海清流生物医药科技有限公司 | A kind of albumen prevents and treats the application in nephrosis drug in preparation |
| CN112716925A (en) * | 2021-02-04 | 2021-04-30 | 福建医科大学附属第一医院 | Application of probucol in preparation of medicine for treating crystal renal disease |
| CN115624566A (en) * | 2022-12-22 | 2023-01-20 | 广东省人民医院 | Peritoneal dialysis solution and preparation method and application thereof |
-
2012
- 2012-07-04 CN CN201210228698.3A patent/CN102716123B/en not_active Expired - Fee Related
Non-Patent Citations (3)
| Title |
|---|
| 徐戈等: "普罗布考和氯沙坦对兔血管成型术后细胞增殖的影响", 《中国医师杂志》 * |
| 杨宁等: "普罗布考-厄贝沙坦读自发性高血压大鼠血压及血清纤溶酶原激活物抑制物1的影响", 《中国高血压杂志》 * |
| 邢妃中等: "IgA肾病的治疗进展", 《中国当代医药》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105250268A (en) * | 2015-10-26 | 2016-01-20 | 白玲强 | Irbesartan composition and application thereof in preparation of drug for treating acute kidney injury |
| CN105250268B (en) * | 2015-10-26 | 2018-08-03 | 白玲强 | Irbesartan composition and its application in the drug for preparing treatment acute kidney injury |
| CN109985230A (en) * | 2018-01-02 | 2019-07-09 | 上海清流生物医药科技有限公司 | A kind of albumen prevents and treats the application in nephrosis drug in preparation |
| CN109985230B (en) * | 2018-01-02 | 2023-10-17 | 上海普佑生物医药有限公司 | Application of protein in preparation of medicine for preventing and treating kidney diseases |
| CN112716925A (en) * | 2021-02-04 | 2021-04-30 | 福建医科大学附属第一医院 | Application of probucol in preparation of medicine for treating crystal renal disease |
| CN115624566A (en) * | 2022-12-22 | 2023-01-20 | 广东省人民医院 | Peritoneal dialysis solution and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102716123B (en) | 2014-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Muszynski et al. | Supernatants from stored red blood cell (RBC) units, but not RBC‐derived microvesicles, suppress monocyte function in vitro | |
| Wang et al. | Sequential blood purification therapy for critical patients with hyperlipidemic severe acute pancreatitis | |
| Wang et al. | Encyclopedia of fecal microbiota transplantation: a review of effectiveness in the treatment of 85 diseases | |
| CN102716123B (en) | Compound preparation for treating IgA nephropathy | |
| Chen et al. | Renoprotective effect of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in advanced chronic kidney disease | |
| Zhu et al. | Inhibiting microRNA-503 and microRNA-181d with losartan ameliorates diabetic nephropathy in KKAy mice | |
| Zhang et al. | Progesterone resistance in endometriosis: current evidence and putative mechanisms | |
| Dhot et al. | Overexpression of endothelial β3‐adrenergic receptor induces diastolic dysfunction in rats | |
| CN103773771A (en) | Transcription factor system as well as preparation method and application thereof | |
| Maduram et al. | Metabolic syndrome in pediatric renal transplant recipients: comparing early discontinuation of steroids vs. steroid group | |
| Elliot et al. | Urine-derived exosomes from individuals with IPF carry pro-fibrotic cargo | |
| Wu et al. | Rat mRNA expression profiles associated with inhibition of ischemic acute kidney injury by losartan | |
| Zhou et al. | Remote ischemic preconditioning ameliorates renal fibrosis after ischemia-reperfusion injury via transforming growth factor beta1 (TGF-β1) signalling pathway in rats | |
| Diao et al. | Therapeutic effects of cationic liposomes on lupus-prone MRL/lpr mice are mediated via inhibition of TLR4-triggered B-cell activation | |
| Munshi et al. | Anti-neutrophil cytoplasmic antibody (ANCA)-negative small vessel vasculitis: A rare cause of pulmonary renal syndrome | |
| Kim et al. | Relapse of minimal change disease following infection with the 2009 pandemic influenza (H1N1) virus | |
| JP2012524248A5 (en) | ||
| Itagaki et al. | Infliximab-and immunosuppressant-resistant Crohn’s disease successfully treated with adsorptive granulocyte apheresis combined with prednisolone | |
| Yi et al. | APLNR is involved in ATRA-induced growth inhibition of nasopharyngeal carcinoma and could suppress EMT process through PI3K/Akt/mTOR signaling pathway | |
| Shimada et al. | A pilot study of leukocytapheresis efficacy with 1.5 liter blood processing volume in patients with ulcerative colitis | |
| El Miedany et al. | Infliximab infusion therapy in inflammatory arthritis: assessment of the accelerated infusion protocol in comparison to the standard infusion approach | |
| Velasco Rodríguez-Belvís et al. | Regain of Response to Adalimumab in a Steroid-Dependent Pediatric Patient With Ulcerative Colitis After Undergoing Selective Granulocyte and Monocyte Apheresis | |
| Rubin et al. | Adalimumab Therapy is Associated with Improvements in Clinical Laboratory Parameters in Patients with Moderately to Severely Active Crohn's Disease: 1243 | |
| Cosnes et al. | Inflammatory bowel disease: from sulfasalazine to biologics | |
| Balwani et al. | MON-041 Renal Biopsy Profile from Central Part of India |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140416 Termination date: 20150704 |
|
| EXPY | Termination of patent right or utility model |